FrancophonIA/ELRC3.0 huggingface dataset:
English: Preparation of the 3 mg vial: carefully add 3 ml of sterile, 9 mg/ml (0.9%) sodium chloride solution for injection to the vial containing the Bortezomib Hospira powder by using a syringe of the appropriate size without removing the vial stopper.
Croatian: Priprema bočice od 3 mg: pažljivo dodajte 3 ml sterilne 0,9%-tne otopine natrijevog klorida za injekciju (9 mg/ml) u bočicu koja sadrži Bortezomib Hospira prašak koristeći štrcaljku odgovarajuće veličine, ne uklanjajući čep s bočice.
English: Intravenous use: Add 2.5 ml 0.9% Sodium Chloride to make 1 mg/ml final concentration.
Croatian: Intravenska primjena: Dodati 2,5 ml 0,9%-tne otopine natrijevog klorida kako bi se pripremila otopina konačne koncentracije 1 mg/ml.
English: • Abnormal reaction to blood transfusions
Croatian: Često abnormalni jetreni enzimi*
English: RECONSTITUTION FOR INTRAVENOUS INJECTION
Croatian: 1. PRIPREMA LIJEKA (REKONSTITUCIJA) ZA PRIMJENU INTRAVENSKOM INJEKCIJOM
English: Subcutaneous use: Add 0.4 ml 0.9% Sodium Chloride to make 2.5 mg/ml final concentration.
Croatian: Potkožna primjena: Dodati 0,4 ml 0,9%-tne otopine natrijevog klorida kako bi se pripremila konačna otopina koncentracije 2,5 mg/ml.
English: Intravenous use: Add 3.5 ml 0.9% Sodium Chloride to make 1 mg/ml final concentration.
Croatian: Intravenska primjena: Dodati 3,5 ml 0,9% otopine natrijevog klorida kako bi se pripremila konačna otopina koncentracije 1 mg/ml.
English: CR+nCR+ PR+MR Median duration Days (months) Time to response CR+PR (days)
Croatian: CR+nCR CR+nCR+PR CR+nCR+ PR+MR
English: Bortezomib Hospira 2.5 mg powder for solution for injection Each 10 ml vial of Bortezomib Hospira 2.5 mg powder for solution for injection must be carefully reconstituted with 1 ml of sodium chloride 9 mg/ml (0.9%) solution for injection, by using a syringe of the appropriate size, without removing the vial stopper.
Croatian: Bortezomib Hospira 2,5 mg prašak za otopinu za injekciju Bočicu od 10 ml lijeka Bortezomib Hospira 2,5 mg praška za otopinu za injekciju mora se pažljivo rekonstituirati pomoću 1 ml 0,9%-tne otopine natrijevog klorida za injekciju (9 mg/ml), uporabom štrcaljke odgovarajuće veličine, bez uklanjanja čepa bočice.
English: LIST OF EXCIPIENTS
Croatian: put primjene
English: Refer to the Summary of Product Characteristics of rituximab for more information.
Croatian: Za više informacija pogledajte sažetak opisa svojstava lijeka za rituksimab.
English: Preparation of the 2.5 mg vial: carefully add 1 ml of sterile, 9 mg/ml (0.9%) sodium chloride solution for injection to the vial containing the Bortezomib Hospira powder by using a syringe of the appropriate size without removing the vial stopper.
Croatian: Priprema bočice od 2,5 mg: pažljivo dodajte 1 ml sterilne 0,9%-tne otopine natrijevog klorida za injekciju (9 mg/ml) u bočicu koja sadrži Bortezomib Hospira prašak koristeći štrcaljku odgovarajuće veličine, ne uklanjajući čep s bočice.
English: Common Eye swelling*, Vision abnormal*, Conjunctivitis* Uncommon Eye haemorrhage*, Eyelid infection*, Chalazion
Croatian: Često oticanje oka*, abnormalan vid*, konjunktivitis*
English: Bortezomib Hospira 1 mg powder for solution for injection Each 5 ml vial of Bortezomib Hospira 1 mg powder for solution for injection must be carefully reconstituted with 0.4 ml of sodium chloride 9 mg/ml (0.9%) solution for injection, by using a syringe of the appropriate size, without removing the vial stopper.
Croatian: Bortezomib Hospira 1 mg prašak za otopinu za injekciju Bočicu od 5 ml lijeka Bortezomib Hospira 1 mg praška za otopinu za injekciju mora se pažljivo rekonstituirati pomoću 0,4 ml 0,9%-tne otopine natrijevog klorida za injekciju (9 mg/ml), uporabom štrcaljke odgovarajuće veličine, bez uklanjanja čepa bočice.
English: Bortezomib Hospira 1 mg powder for solution for injection Each 5 ml vial of Bortezomib Hospira 1 mg powder for solution for injection must be carefully reconstituted with 1 ml of sodium chloride 9 mg/ml (0.9%) solution for injection, by using a syringe of the appropriate size, without removing the vial stopper.
Croatian: Bortezomib Hospira 1 mg prašak za otopinu za injekciju Bočicu od 5 ml lijeka Bortezomib Hospira 1 mg praška za otopinu za injekciju mora se pažljivo rekonstituirati pomoću 1 ml 0,9%-tne otopine natrijevog klorida za injekciju (9 mg/ml), uporabom štrcaljke odgovarajuće veličine, bez uklanjanja čepa bočice.
English: Discontinue Bortezomib Hospira if PML is diagnosed.
Croatian: Ako je dijagnosticiran PML, liječenje lijekom Bortezomib Hospira treba prekinuti.
English: Intravenous use: Add 1 ml 0.9% Sodium Chloride to make 1 mg/ml final concentration.
Croatian: Intravenska primjena: Dodati 1 ml 0,9%-tne otopine natrijevog klorida kako bi se pripremila konačna otopina koncentracije 1 mg/ml.
English: Common Leukopenia*, Lymphopenia* Uncommon Pancytopenia*, Febrile neutropenia, Coagulopathy*, Leukocytosis*,
Croatian: Manje često pancitopenija*, febrilna neutropenija, koagulopatija*, leukocitoza*, limfadenopatija, hemolitička anemija
English: Subcutaneous use: Add 1.2 ml 0.9% Sodium Chloride to make 2.5 mg/ml final concentration.
Croatian: Potkožna primjena: Dodati 1,2 ml 0,9%-tne otopine natrijevog klorida kako bi se pripremila konačna otopina koncentracije 2,5 mg/ml.
English: Intravenous use: Add 3 ml 0.9% Sodium Chloride to make 1 mg/ml final concentration.
Croatian: Intravenska primjena: Dodati 3 ml 0,9%-tne otopine natrijevog klorida kako bi se pripremila konačna otopina koncentracije 1 mg/ml.
English: Bortezomib Hospira is administered via intravenous or subcutaneous injection at the recommended dose of 1.3 mg/m2 body surface area twice weekly for two weeks on days 1, 4, 8, and 11 in a 21 day treatment cycle.
Croatian: Bortezomib Hospira primjenjuje se putem intravenske ili supkutane injekcije u preporučenoj dozi od 1,3 mg/m2 površine tijela, dva puta tjedno tijekom dva tjedna, na 1., 4., 8. i 11. dan, u ciklusu liječenja od 21 dana.
English: Macrophage activation
Croatian: Operativni i medicinski postupci Rijetko aktivacija makrofaga
English: Subcutaneous use: Add 1.4 ml 0.9% Sodium Chloride to make 2.5 mg/ml final concentration.
Croatian: Potkožna primjena: Dodati 1,4 ml 0,9% otopine natrijevog klorida kako bi se pripremila konačna otopina koncentracije 2,5 mg/ml.
English: 1.1 Preparation of the 1 mg vial: carefully add 0.4 ml of sterile, 9 mg/ml (0.9%) sodium chloride solution for injection to the vial containing the Bortezomib Hospira powder by using a syringe of the appropriate size without removing the vial stopper.
Croatian: Priprema bočice od 1 mg: pažljivo dodajte 0,4 ml sterilne 0,9%-tne otopine natrijevog klorida za injekciju (9 mg/ml) u bočicu koja sadrži Bortezomib Hospira prašak koristeći štrcaljku odgovarajuće veličine, ne uklanjajući čep s bočice.
English: 222 subjects were enrolled into the study; 221 subjects were treated with bortezomib Hazards ratio estimate is based on a Cox model adjusted for stratification factors: ISS staging and number of prior lines.
Croatian: Procjena omjera hazarda temelji se na Coxovom modelu prilagođenom prema čimbenicima stratifikacije: ISS stupnjevanje i broj prethodnih linija.
English: Subcutaneous use: Add 1 ml 0.9% Sodium Chloride to make 2.5 mg/ml final concentration.
Croatian: Potkožna primjena: Dodati 1 ml 0,9%-tne otopine natrijevog klorida kako bi se pripremila konačna otopina koncentracije 2,5 mg/ml.
English: Main efficacy results are presented in Table 13.
Croatian: Glavni rezultati djelotvornosti prikazani su u Tablici
English: Oedema (inc peripheral), Chills, Injection site reaction*, Malaise*
Croatian: Vrlo često pireksija*, umor, astenija Često edem (uključujući periferni), zimica, reakcija na mjestu injekcije*, malaksalost*
English: Table 2: Recommended posology for Bortezomib Hospira in combination with melphalan and prednisone Twice weekly Bortezomib Hospira (cycles 1-4)
Croatian: Tablica 2: Preporučeno doziranje lijeka Bortezomib Hospira kada se primjenjuje u kombinaciji s melfalanom i prednizonom
English: Day 1 -- -- Day 4 Day 8 Day rest period
Croatian: 8., 11. dan period odmora period odmora
English: • Cerebrovascular disorders
Croatian: Manje često cerebrovaskularni događaj
English: • seizures
Croatian: Prijavljivanje nuspojava
English: • Fluid retention
Croatian: • mjere opreza čuvanja pripremljene otopine
English: • shortness of breath or cough
Croatian: Poremećaji jetre i žuči
English: 1.1 Preparation of the 1mg vial: carefully add 1mlof sterile, 9 mg/ml (0.9%) sodium chloride solution for injection to the vial containing the Bortezomib Hospira powder by using a syringe of the appropriate size without removing the vial stopper.
Croatian: Priprema bočice od 1 mg: pažljivo dodajte 1 ml sterilne 0,9%-tne otopine natrijevog klorida za injekciju (9 mg/ml) u bočicu koja sadrži Bortezomib Hospira prašak koristeći štrcaljku odgovarajuće veličine, ne uklanjajući čep s bočice.
English: This should be checked regularly.
Croatian: Potrebno ju je redovito provjeravati.
English: The recommended daily dose is 0.34 ml per kilogram body weight.
Croatian: Preporučena dnevna doza jest 0,34 ml po kilogramu tjelesne težine.
English: Vedrop has been authorised under ‘exceptional circumstances'.
Croatian: Lijek Vedrop odobren je u „iznimnim okolnostima”.
English: Vedrop tocofersolan
Croatian: Vedrop tokofersolan
English: What is Vedrop and what is it used for?
Croatian: Što je Vedrop i za što se koristi?
English: It has a number of actions in the body, including protecting the nervous system from damage.
Croatian: U tijelu ima brojna djelovanja, uključujući zaštitu živčanog sustava od oštećenja.
English: The full EPAR for Vedrop can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Croatian: Cjelovito europsko javno izvješće o procjeni (EPAR) lijeka Vedrop nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: This is because it has not been possible to obtain complete information about Vedrop due to the rarity of the disease.
Croatian: Razlog za to je nemogućnost dobivanja potpunih informacija o lijeku Vedrop zbog rijetkosti bolesti.
English: The company also presented information on the use of Vedrop in patients with cystic fibrosis, but withdrew its application for this disease during the evaluation of the medicine.
Croatian: Tvrtka je također prikazala informacije o uporabi lijeka Vedrop u bolesnika s cističnom fibrozom, no povukla je svoj zahtjev za tu bolest tijekom procjene lijeka.
English: What measures are being taken to ensure the safe and effective use of Vedrop?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Vedrop?
English: The European Commission granted a marketing authorisation valid throughout the European Union for Vedrop on 24 July 2009.
Croatian: Europska komisija izdala je odobrenje za stavljanje lijeka Vedrop u promet koje vrijedi na prostoru Europske unije od 24. srpnja 2009.
English: This is a summary of the European public assessment report (EPAR) for Vedrop.
Croatian: Ovo je sažetak europskoga javnog izvješća o procjeni (EPAR) lijeka Vedrop.
English: Vitamin E is a natural substance that cannot be made by the body and is therefore needed in the diet.
Croatian: Vitamin E prirodna je tvar koju tijelo ne može proizvesti i koja je stoga potrebna u prehrani.
English: Vedrop must not be used in premature babies.
Croatian: Lijek Vedrop ne smije se primjenjivati u prijevremeno rođene djece.
English: The main measures of effectiveness were the level of vitamin E in the blood and the number of children whose neurological symptoms improved or stayed the same.
Croatian: Glavne mjere djelotvornosti bile su razina vitamina E u krvi i broj djece u koje su se neuorološki simptomi poboljšali ili ostali isti.
English: To support the use of Vedrop, the company presented information from the scientific literature, including the results of three studies in a total of 92 children and adolescents with chronic cholestasis who were given tocofersolan for about two years.
Croatian: Kako bi iznijela dokaze u korist uporabe lijeka Vedrop, tvrtka je prikazala informacije iz znanstvene literature, uključujući rezultate triju ispitivanja kojima je bilo obuhvaćeno ukupno 92 djece i adolescenata s kroničnom kolestazom koji su primali tokofersolan otprilike dvije godine.
English: What are the risks associated with Vedrop?
Croatian: Koji su rizici povezani s lijekom Vedrop?
English: Other information about Vedrop
Croatian: Ostale informacije o lijeku Vedrop
English: It is used in children up to the age of 18 years who have congenital or hereditary chronic cholestasis and who cannot absorb vitamin E from the gut.
Croatian: Primjenjuje se u djece u dobi do 18 godina koja imaju kongenitalnu ili hereditarnu kroničnu kolestazu i koja ne mogu apsorbirati vitamin E iz crijeva.
English: Vedrop is a medicine used to treat or prevent vitamin E deficiency (low vitamin E levels).
Croatian: Vedrop je lijek koji se koristi za liječenje ili prevenciju manjka vitamina E (niske razine vitamina E).
English: This can increase vitamin E levels in the blood and help to prevent damage to the nervous system due to vitamin E deficiency.
Croatian: To može povećati razinu vitamina E u krvi i pomoći u prevenciji oštećenja živčanog sustava zbog manjka vitamina E.
English: All the patients had vitamin E deficiency that was not responding to other vitamin E treatments given by mouth.
Croatian: Svi bolesnici imali su manjak vitamina E te nisu pozitivno odgovorili na druge terapije vitaminom E primjenjivane kroz usta.
English: Why is Vedrop approved?
Croatian: Zašto je lijek Vedrop odobren?
English: The most common side effect with Vedrop (which may affect up to 1 in 10 people) is diarrhoea.
Croatian: Najčešća je nuspojava lijeka Vedrop (može se javiti u više od 1 na 10 osoba) proljev.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Vedrop have been included in the summary of product characteristics and the package leaflet.
Croatian: Preporuke i mjere opreza kojih se zdravstveni djelatnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Vedrop nalaze se u sažetku opisa svojstava i u uputi o lijeku.
English: The studies showed that Vedrop could correct vitamin E levels in patients with chronic cholestasis and that it might improve or prevent neurological symptoms, especially in patients aged below three years.
Croatian: Ispitivanja su pokazala da bi lijek Vedrop mogao ispraviti razinu vitamina E u bolesnika s kroničnom kolestazom i poboljšati ili spriječiti neuorološke simptome, posebno u bolesnika mlađih od tri godine.
English: Congenital or hereditary chronic cholestasis is an inherited disease causing problems with the flow of bile from the liver to the gut.
Croatian: Kongenitalna ili hereditarna kronična kolestaza naslijeđena je bolest koja uzrokuje probleme s protokom žuči iz jetre u crijeva.
English: Since Vedrop has been approved under exceptional circumstances, the company that markets the medicine is required to provide further data on the safety and effectiveness of Vedrop in patients with congenital or hereditary chronic cholestasis.
Croatian: Budući da je lijek Vedrop odobren u iznimnim okolnostima, tvrtka koja lijek stavlja u promet obvezna je pružiti dodatne podatke o sigurnosti i djelotvornosti lijeka Vedrop u bolesnika s kongenitalnom ili hereditarnom kroničnom kolestazom.
English: Because vitamin E dissolves in fats but not in water, it can only be absorbed from the gut into the body alongside fat particles.
Croatian: Vitamin E razgrađuje se u mastima, ali ne i u vodi, i stoga se iz crijeva može apsorbirati u tijelo samo uz čestice masti.
English: It is not intended to provide practical advice on how to use Vedrop.
Croatian: Svrha sažetka nije davati praktične savjete o primjeni lijeka Vedrop.
English: This dose should be adjusted according to the amount of vitamin E in the patient's blood.
Croatian: Tu je dozu potrebno prilagoditi u skladu s razinom vitamina E u bolesnikovoj krvi.
English: Patients with cholestasis may have low vitamin E levels because they have problems absorbing fats from the gut.
Croatian: Bolesnici s kolestazom mogu imati nisku razinu vitamina E jer imaju problema s apsorbiranjem masti iz crijeva.
English: The European Medicines Agency decided that Vedrop's benefits are greater than its risks and recommended that Vedrop be given marketing authorisation.
Croatian: Europska agencija za lijekove zaključila je da koristi lijeka Vedrop nadmašuju s njim povezane rizike te je preporučila davanje odobrenja za stavljanje lijeka u promet.
English: For more information about treatment with Vedrop, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Croatian: Više informacija o liječenju lijekom Vedrop pročitajte u uputi o lijeku (također dio EPAR-a), odnosno obratite se svojem liječniku ili ljekarniku.
English: What information is still awaited for Vedrop?
Croatian: Koje se još informacije očekuju o lijeku Vedrop?
English: Vedrop can only be obtained with a prescription and treatment should be started and supervised by a doctor who has experience in treating patients with congenital or hereditary chronic cholestasis.
Croatian: Lijek Vedrop izdaje se samo na recept, a liječenje treba započeti i nadzirati liječnik s iskustvom u liječenju bolesnika s kongenitalnom ili hereditarnom kroničnom kolestazom.
English: Tocofersolan can be absorbed from the gut in children who have difficulty absorbing fats and vitamin E from the diet.
Croatian: Tokofersolan se može apsorbirati iz crijeva u djece s teškoćama u apsorbiranju masti i vitamina E iz hrane.
English: The active substance in Vedrop, tocofersolan, is vitamin E that has been made water soluble by attaching it to a chemical called polyethylene glycol.
Croatian: Djelatna tvar u lijeku Vedrop, tokofersolan, jest vitamin E koji je vezivanjem na kemikaliju koja se naziva polietilen glikol postao topiv u vodi.
English: How is Vedrop used?
Croatian: Kako se Vedrop koristi?
English: Vedrop is available as a solution to be given by mouth.
Croatian: Lijek Vedrop dostupan je u obliku otopine koja se daje kroz usta.
English: Bile is a fluid produced in the liver that helps to absorb fats from the gut.
Croatian: Žuč je tekućina koja se proizvodi u jetri i koja pomaže u apsorpciji masti iz crijeva.
English: Vedrop contains the active substance tocofersolan.
Croatian: Lijek Vedrop sadržava djelatnu tvar tokofersolan.
English: For the full list of all side effects and restrictions with Vedrop, see the package leaflet.
Croatian: Potpuni popis svih nuspojava i ograničenja pri primjeni lijeka Vedrop potražite u uputi o lijeku.
English: How does Vedrop work?
Croatian: Kako djeluje Vedrop?
English: For practical information about using Vedrop, patients should read the package leaflet or contact their doctor or pharmacist.
Croatian: Praktične informacije o primjeni lijeka Vedrop bolesnici trebaju pročitati u uputi o lijeku, odnosno obratiti se svojem liječniku ili ljekarniku.
English: What benefits of Vedrop have been shown in studies?
Croatian: Koje su koristi lijeka Vedrop utvrđene u ispitivanjima?
English: You must use an effective method of contraception.
Croatian: Morate koristiti djelotvornu metodu kontracepcije.
English: Usually this is for at least 6 to 12 months and may be for many years.
Croatian: Obično je to najmanje 6 - 12 mjeseci, no može potrajati i godinama.
English: Expected:
Croatian: Očekivano:
English: Keep the tablet bottle with you so that you can easily describe what you have taken.
Croatian: Ponesite bocu s tabletama sa sobom kako biste mogli lako opisati što ste uzeli.
English: The recommended dose is one tablet once a day with food.
Croatian: Preporučena doza je jedna tableta jedanput na dan s hranom.
English: Date of first authorisation: 09 January 2017
Croatian: Datum prvog odobrenja: 09. siječanj 2017.
English: The clinical relevance of these substitutions is not known.
Croatian: Klinička značajnost tih supstitucija nije poznata.
English: Angioedema1, urticaria1
Croatian: Angioedem1, urtikarija1
English: You can still infect others when taking this medicine.
Croatian: Druge osobe možete zaraziti i tijekom uzimanja ovoga lijeka.
English: Treatment should continue for as long as your doctor tells you.
Croatian: Liječenje traje onoliko dugo koliko Vam kaže Vaš liječnik.
English: b All No Effect Boundaries are 70%-143%.
Croatian: Sve granice bez učinka iznose od 70% do 143% c.
English: How to take Vemlidy Always take this medicine exactly as your doctor has told you.
Croatian: Kako uzimati Vemlidy Uvijek uzmite ovaj lijek točno onako kako Vam je rekao liječnik.
English: • Take care not to pass on your hepatitis B to other people.
Croatian: • Pazite da ne prenesete hepatitis B na druge osobe.
English: Contact your doctor or nearest emergency department immediately for advice.
Croatian: Odmah zatražite savjet liječnika ili najbliže hitne medicinske službe.
English: • Swelling of the face, lips, tongue or throat (angioedema)
Croatian: • oticanje lica, usana, jezika ili grla (angioedem)
English: N/A = not applicable
Croatian: N/P = nije primjenjivo
English: • Tell your doctor immediately about new or unusual symptoms after you stop treatment, particularly symptoms you associate with hepatitis B infection.
Croatian: • Odmah obavijestite liječnika o novim ili neuobičajenim simptomima nakon što prekinete liječenje, osobito o simptomima koje povezujete s infekcijom hepatitisom B.
English: If you do miss a dose, work out how long since you should have taken it.
Croatian: Ako propustite uzeti dozu, izračunajte koliko je vremena prošlo od vremena kada ste je trebali uzeti.
English: a All interaction studies are conducted in healthy volunteers.
Croatian: Sva ispitivanja interakcija provedena su na zdravim dobrovoljcima b.
English: The use of Vemlidy may be considered during pregnancy, if necessary.
Croatian: Može se razmotriti primjena lijeka Vemlidy tijekom trudnoće ako je neophodno.
English: The most frequently reported adverse reactions were headache (12%), nausea (6%), and fatigue (6%).
Croatian: Najčešće zabilježene nuspojave bile su glavobolja (12%), mučnina (6%) i umor (6%).
English: Other medicines and Vemlidy Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Croatian: Drugi lijekovi i Vemlidy Obavijestite svog liječnika ili ljekarnika ako uzimate, nedavno ste uzeli ili biste mogli uzeti bilo koje druge lijekove.
English: HBV transmission
Croatian: Prijenos HBV-a
English: Your doctor may need to carry out blood tests to monitor your liver function.
Croatian: Liječnik će možda morati provesti krvne pretrage radi praćenja funkcije jetre.
English: Frequencies are defined as follows: very common (≥ 1/10), common (≥ 1/100 to < 1/10) or uncommon (≥ 1/1,000 to < 1/100).
Croatian: Učestalosti su definirane na sljedeći način: vrlo često (≥ 1/10), često (≥ 1/100 i < 1/10) ili manje često (≥ 1/1000 i < 1/100).
English: With prolonged treatment for more than 2 years, regular reassessment is recommended to confirm that continuing the selected therapy remains appropriate for the patient.
Croatian: Tijekom produljenog liječenja koje traje dulje od 2 godine preporučuju se redoviti pregledi kako bi se potvrdilo da je nastavak odabrane terapije i dalje prikladan za bolesnika.
English: Vemlidy [Outer packaging only]
Croatian: Vemlidy [samo vanjsko pakiranje]
English: What Vemlidy is and what it is used for
Croatian: Što je Vemlidy i za što se koristi
English: Discuss with your doctor the precautions needed to avoid infecting others.
Croatian: Razgovarajte s liječnikom o mjerama opreza potrebnima za sprječavanje prenošenja infekcije na druge osobe.
English: Treatment of overdose with Vemlidy consists of general supportive measures including monitoring of vital signs as well as observation of the clinical status of the patient.
Croatian: Liječenje predoziranja lijekom Vemlidy sastoji se od općih potpornih mjera, uključujući praćenje vitalnih znakova, kao i promatranje kliničkog statusa bolesnika.
English: Patients with creatinine clearance < 30 mL/min
Croatian: Bolesnici s klirensom kreatinina < 30 ml/min